Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

被引:150
|
作者
Petroff, MGV
Egan, JM
Wang, XL
Sollott, SJ
机构
[1] NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[2] NIA, Diabet Sect, Gerontol Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA
[3] Univ Nacl La Plata, Fac Ciencias Med, Ctr Invest Cardiovasc, La Plata, Buenos Aires, Argentina
关键词
cardiac myocytes; glucagon-like peptide-1; cAMP; calcium;
D O I
10.1161/hh1701.095716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The gut hormone, glucagon-like peptide-1 (GLP-1), which is secreted in nanomolar amounts in response to nutrients in the intestinal lumen, exerts cAMP/protein kinase A-mediated insulinotropic actions in target endocrine tissues, but its actions in heart cells are unknown. GLP-1 (10 nmol/L) increased intracellular cAMP (from 5.7+/-0.5 to 13.1 +/- 0.12 pmol/mg protein) in rat cardiac myocytes. The effects of cAMP-doubling concentrations of both GLP-1 and isoproterenol (ISO. 10 nmol/L) on contraction amplitude, intracellular Ca2+ transient (CaT), and pH(i) in indo-1 and seminaphthorhodafluor (SNARF)-1 loaded myocytes were compared. Whereas ISO caused a characteristic increase (above baseline) in contraction amplitude (160+/-34%) and CaT (70+/-5%), GLP-1 induced a significant decrease in contraction amplitude (-27+/-5%) with no change in the CaT after 20 minutes. Neither pertussis toxin treatment nor exposure to the cGMP-stimulated phosphodiesterase (PDE2) inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine or the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine nor the phosphatase inhibitors okadaic acid or calyculin A unmasked an ISO-mimicking response of GLP-1. In SNARF-1-loaded myocytes, however, both ISO and GLP-1 caused an intracellular acidosis (Delta pH(i) -0.09+/-0.02 and -0.08+/-0.03, respectively). The specific GLP-1 antagonist exendin 9-39 and the cAMP inhibitory analog Rp-8CPT-cAMPS inhibited both the GLP-1-induced intracellular acidosis and the negative contractile effect. We conclude that in contrast to beta -adrenergic signaling, GLP-1 increases cAMP but fails to augment contraction, suggesting the existence of functionally distinct adenylyl cyclase/cAMP/protein kinase A compartments, possibly determined by unique receptor signaling microdomains that are not controlled by pertussis toxin-sensitive G proteins or by enhanced local PDE or phosphatase activation. Furthermore, GLP-1 elicits a cAMP-dependent modest negative inotropic effect produced by a decrease in myofilament-Ca2+ responsiveness probably resulting from intracellular acidification.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 50 条
  • [21] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [22] Glucagon-like peptide-1 prolongs cardiac action potential duration
    Xiao, Yong-Fu
    Nikolskaya, Alena
    Jaye, Deborah A.
    Sigg, Daniel C.
    FASEB JOURNAL, 2009, 23
  • [23] Glucagon-like peptide-1 receptor mediated control of cardiac energy
    Al Batran, Rami
    Almutairi, Malak
    Ussher, John R.
    PEPTIDES, 2018, 100 : 94 - 100
  • [24] Cardiac function in mice lacking the glucagon-like peptide-1 receptor
    Gros, R
    You, XM
    Baggio, LL
    Kabir, MG
    Sadi, AM
    Mungrue, IN
    Parker, TG
    Huang, QL
    Drucker, DJ
    Husain, M
    ENDOCRINOLOGY, 2003, 144 (06) : 2242 - 2252
  • [25] Glucagon-Like Peptide-1 Receptor Agonists
    Edelman, Steven V.
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S12 - S16
  • [26] Glucagon-like peptide-1, a matter of taste?
    Jensterle, Mojca
    DeVries, J. Hans
    Battelino, Tadej
    Battelino, Saba
    Yildiz, Bulent
    Janez, Andrej
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04): : 763 - 775
  • [27] Glucagon-Like Peptide-1 Gene Therapy
    Rowzee, Anne M.
    Cawley, Niamh X.
    Chiorini, John A.
    Di Pasquale, Giovanni
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [28] Is ghrelin a glucagon-like peptide-1 secretagogue?
    Ueno, Hiroaki
    Nakazato, Masamitsu
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 466 - 467
  • [29] Glucagon-like peptide-1 and safety - Reply
    Bloom, SR
    NATURE, 1997, 385 (6613) : 214 - 214
  • [30] Glucagon-Like Peptide-1 and Diabetes 2012
    Monami, Matteo
    Di Pasquale, Giovanni
    Rowzee, Anna
    Rotella, Carlo Maria
    Mannucci, Edoardo
    EXPERIMENTAL DIABETES RESEARCH, 2012,